drugset
drugset / Trial / NCT05106972

Umbilical Cord Mesenchymal Stem Cell Transplantation for Decompensated Hepatitis B Cirrhosis

NCT05106972 ↗

Unknown 30 enrolled Asia Stem Cell Regenerative Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This study aims to evaluate the safety and clinical efficacy of umbilical cord mesenchymal stem cell transplantation for decompensated hepatitis B cirrhosis.

Timeline

Start
2021-12-01
Primary completion
2024-12-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject human umbilical cord mesenchymal stem cells Cell therapy 1e+08 cells Intravenous

Indications

cirrhosis of liver